# US 2025/0205155 A1 · Formulations comprising melphalan flufenamide and cyclodextrin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205155 A1
- Document ID: US20250205155A1
- Status: Published application
- Kind: A1
- Application number: 18/849,977
- Filed: 2023-03-24
- Published: 2025-06-26
- Earliest claimed: 2022-03-24
- Assignees: Oncopeptides Innovation AB
- Applicants: Oncopeptides Innovation AB
- Inventors: Fredrik LEHMANN; Peter TEODOROVIC; Kristin HAMMER; Rune RINGOM
- Web page: https://patentgrep.com/patent/US20250205155A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a pharmaceutical preparation comprising melphalan flufenamide, or a salt thereof, and γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin. The invention further provides compositions comprising the pharmaceutical preparation of the invention, and kits and uses of the pharmaceutical preparations of the invention.

## Claims

### Claim 1

A pharmaceutical preparation comprising melphalan flufenamide, or a salt thereof, and γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin.

### Claim 2 (depends on 1)

The pharmaceutical preparation of claim 1, wherein the weight ratio (w/w) between the γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin and melphalan flufenamide is 1:1 to 100:1, 4:1 to 80:1, 5:1 to 25:1, or 10:1 to 25:1.

### Claim 3 (depends on 1, 2)

The pharmaceutical preparation of claim 1 or 2, wherein said pharmaceutical preparation is a lyophilized powder.

### Claim 4 (depends on 3)

The pharmaceutical preparation of claim 3, wherein the pharmaceutical preparation comprises 1 mg to 30 mg melphalan flufenamide (excluding the mass of any counterion).

### Claim 5 (depends on 4)

The pharmaceutical preparation of claim 4, comprising sucrose.

### Claim 6 (depends on 5)

The pharmaceutical preparation of claim 5, wherein the weight ratio (w/w) of sucrose to melphalan flufenamide is 25:1 to 75:1, for example 50:1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The pharmaceutical preparation of any one of claims 1 to 6, which is substantially free from organic solvent.

### Claim 8 (depends on 1, 2)

The pharmaceutical preparation of any one of claims 1 or 2, wherein said pharmaceutical preparation is a liquid formulation comprising propylene glycol.

### Claim 9 (depends on 8)

The pharmaceutical preparation of claim 8, wherein said melphalan flufenamide, or salt thereof, is at a concentration of about 10 mg/mL to about 50 mg/mL (excluding the mass of any counterion).

### Claim 10 (depends on 9)

The pharmaceutical preparation of claim 9, wherein said melphalan flufenamide, or salt thereof, is at a concentration of about 15 mg/mL to about 25 mg/mL (excluding the mass of any counterion).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The pharmaceutical preparation of any one of claims 1 to 10, comprising one or more additional therapeutic agent(s) selected from the group consisting of a protease inhibitor (PI), an immunomodulatory drug (IMiD), an alkylator and a monoclonal antibody (for example an anti-CD38 antibody or an anti-SLAMF7 antibody).

### Claim 12 (depends on 3, 4, 5, 6, 7)

The pharmaceutical preparation of any one of claims 3 to 7, wherein said pharmaceutical preparation consists essentially of melphalan flufenamide, or a salt thereof, γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin, and sucrose.

### Claim 13 (depends on 8, 9, 10)

The pharmaceutical preparation of any one of claims 8 to 10, wherein said pharmaceutical preparation consists essentially of melphalan flufenamide, or a salt thereof; γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin; and propylene glycol and/or PEG.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The pharmaceutical preparation of any one of claims 1 to 13, wherein the melphalan flufenamide is in the form of its hydrochloride salt.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The pharmaceutical preparation of any one of claims 1 to 14, wherein the melphalan flufenamide is deuterated melphalan flufenamide, preferably the deuterated melphalan flufenamide has the structure

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The pharmaceutical preparation of any one of claims 1 to 15, wherein the pharmaceutically acceptable derivative of γ-cyclodextrin is selected from the group consisting of hydroxypropyl-γ-cyclodextrin, succinyl-γ-cyclodextrin, sulfobutyl ether-γ-cyclodextrin, γ-cyclodextrin phosphate sodium salt, γ-cyclodextrin sulphate sodium salt, 2-carboxyethyl-γ-cyclodextrin, acetylated-γ-cyclodextrin, and sugammadex; and preferably wherein the pharmaceutically acceptable derivative of γ-cyclodextrin is hydroxypropyl-γ-cyclodextrin.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The pharmaceutical preparation of any one of claims 1 to 16, wherein the weight ratio (w/w) between the γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin and melphalan flufenamide is 15:1 to 25:1, for example 20:1 to 25:1.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A composition comprising a pharmaceutical preparation of any of claims 1 to 17 and a physiologically acceptable aqueous solvent or diluent.

### Claim 19

A composition comprising melphalan flufenamide, or a salt thereof, γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin, and a physiologically acceptable aqueous solvent.

### Claim 20 (depends on 18, 19)

The composition of claim 18 or claim 19, wherein the physiologically acceptable aqueous solvent is a glucose solution, a saline solution, or a mixture thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A kit comprising a pharmaceutical preparation of any of claims 1 to 17 and a physiologically acceptable aqueous solvent or diluent.

### Claim 22

A kit comprising melphalan flufenamide, or a salt(s) thereof, γCD or a pharmaceutically acceptable derivative of γ-cyclodextrin, and optionally one or more physiologically acceptable aqueous solvent or diluent.

### Claim 23 (depends on 21)

The kit of claim 21 wherein the melphalan flufenamide, or a salt(s) thereof, is provided as a lyophilised preparation comprising (or consisting essentially of) melphalan flufenamide and sucrose, or provided as a liquid pharmaceutical formulation comprising (or consisting essentially of) melphalan flufenamide and propylene glycol and/or polyethylene glycol.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The pharmaceutical preparation of claims 1 to 17, or the composition of claims 18, 19 or 20, or the kit of claims 21, 22 or 23, for use as a medicament.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The pharmaceutical preparation of any one of claims 1 to 17, or the composition of claims 18, 19 or 20, or the kit of claims 21, 22 or 23, for use in treatment or prophylaxis of a disease or condition that may be treated with conventional chemotherapy agents, for example, with an alkylator (e.g. melphalan, cyclophosphamide and bendamustine).

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The pharmaceutical preparation of any one of claims 1 to 17, or the composition of claims 18, 19 or 20, or the kit of claims 21, 22 or 23, for use in the treatment or prophylaxis of cancer or for use in the treatment or prophylaxis of amyloidosis.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The pharmaceutical preparation of any one of claims 1 to 17, or the composition of claims 18, 19 or 20, or the kit of claims 21, 22 or 23, for use in the treatment or prophylaxis of cancer wherein the cancer is selected from the group consisting of multiple myeloma, breast cancer, lung cancer, ovarian cancer, glioblastoma, leukaemias and lymphomas.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method for treating a patient which comprises administering a pharmaceutically effective amount of the pharmaceutical preparation of any one of claims 1 to 17 or the composition of claims 18, 19 or 20 to a subject in need thereof.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method for the treatment or prophylaxis of cancer, comprising administering an effective amount of the pharmaceutical preparation of any one of claims 1 to 17, or the composition of claims 18, 19 or 20, to a subject in need thereof.
